Thanks everyone for joining us again this year for the Guggenheim Healthcare Innovation Conference. I'm Vamil Divan, one of the biopharma analysts here at Guggenheim. Joining us next in this room, we have the ProKidney team. Next to me, we have Bruce Culleton, the CEO, and we have Anthony Conway, Head of R&D, and then we have Greg Madison on the CCO at the end of the group here. So thanks again for joining us. Maybe, Bruce, I'll turn to you first, just for people who are maybe a little less familiar with the ProKidney story, just a little bit of an overview on the company, and obviously exciting times. A lot of exciting stuff coming up in the next few months. Kind of set the stage, and then we'll go deeper from there.
Sure. Okay. Well, thanks, Vamil, for having us here again. So, I'll just talk about our purpose, our progress, and a little bit about our people too. So we've got 250 employees. Most of them are in North Carolina, or the majority of them are in North Carolina, where we have our manufacturing operations. We have a single purpose as a company, and that single purpose is to stabilize kidney function in patients with advanced chronic kidney disease and diabetes, and give them hope to stay away from dialysis for as long as possible. We have a single asset. The asset's called rilparencel. It's an autologous cell therapy. The cells are harvested through a standard kidney biopsy, expanded ex vivo, and then re-injected back into the kidneys. We've made substantial progress in our clinical development. We're a late-stage clinical development, very late stage. We've completed recruitment.
We should finish enrollment in Q1 2027, and we expect an accelerated approval readout in Q2 2027.
Great. Thanks for that overview. So maybe you can just remind us, I think, very interesting, exciting data you've shared to date for rilparencel, maybe just an overview on what you've shared, and then also the stage for the ongoing work.
Sure. This will be a really quick summary of what we've shared. We could spend the rest of the time just talking about the data. I'll focus on our REGEN-007 trial that was published in May of this year in the Clinical Journal of the American Society of Nephrology. In one group, one pre-specified group, the 24 patients who were in the group that most looks like how we treat patients in our phase III trial, so a very similar treatment profile, we saw in that a 4.5 mL per minute annualized difference, or a 78% improvement in patients' slope of kidney function decline before treatment with rilparencel versus after treatment. Again, that was a 78% improvement in decline in kidney function. That was from that study.
The other phase II trial that I'll speak of just briefly was the RMCL-002 study, and in that study, we saw the benefit associated with rilparencel treatment really highlighted in the patients who are at highest risk of kidney failure, those with a GFR less than 30. Based upon that information, we did change our phase III protocol to be more focused on patients who've got that highest risk of kidney failure.
Okay. Maybe you can talk about the ongoing trial now. Currently, you mentioned the accelerated endpoint readout. Second quarter of next year. What are you hoping to see? How is the study designed for that, and then also for the final readout?
Sure. We have a very rigorous phase III trial. It is for cell therapy. It is a randomized, sham-controlled, two-arm, blinded study. Eligible patients have a GFR between 20 and 35. They have to have diabetes, and they have to have a diagnosis of chronic kidney disease. After randomization, patients are allocated to receive rilparencel, which is, once the product is made, there is an injection into the biopsied kidney, and then three months later, an injection into the contralateral kidney. The sham group is a true sham group. In that arm of the study, patients actually do have sham procedures, and for all intents and purposes, they believe that they are actually getting a biopsy and a rilparencel treatment. The endpoints, there are two ways to think about this. It is one trial. There is an accelerated approval endpoint, which is eGFR slope.
We are looking for the difference between the treatment and the control group in eGFR slope. That is the accelerated approval readout, which is again expected in Q2 of next year. The same patients, the same trial, will then be followed until we get to a confirmatory endpoint. Assuming we get accelerated approval, that confirmatory endpoint is a time to composite of events, and that composite event includes a 40% loss in eGFR, a sustained eGFR less than 15, dialysis or transplant, or renal or cardiovascular death. Same study, different endpoints, accelerated approval, and confirmatory endpoint.
For the accelerated endpoint, you mentioned the prior trial where you showed a 74% benefit in sort of pre-treatment, post-treatment here. You will have the comparator arm. On that accelerated endpoint, what can you share about what you need to show from a statistical perspective, but also clinically will be meaningful?
Yeah.
Difference between the two groups?
Yeah. So, great question. We've assumed in the control group a decline in kidney function of 3 mLs per minute per year. That assumption was based upon our view of the entire data that's accessible to us in this population. I'll remind you that in our phase II study that I just mentioned, the decline in the control group was closer to six mLs per minute per year. So, we've actually taken a very conservative approach to what we expect in the control group for our phase III study. We expect the decline in the treated group to be 1.5 mLs per minute per year, a 50% difference. When we talk to KOLs, when we talk to nephrologists, that 1.5 mL per minute difference between the two groups is clinically meaningful, especially in this patient population.
It's also a 50% difference between the two groups, and that translates easily into how much time you could prevent someone from needing dialysis. So, those numbers resonate well with providers, they resonate well with patients, and we believe they'll also resonate well with payers.
Okay. Maybe you can talk then just about the unmet needs of the population you'd be targeting. I think you shared a little more of this in your updated corporate presentation today. Just how are you viewing this opportunity commercially?
Greg, do you want to just talk to us about that commercially? I'll hand it over to Greg to take us through how we're thinking about this opportunity commercially.
Yeah. I think as Bruce started to allude to here, despite the advances recently in chronic kidney disease with a lot of new therapies coming online, the bottom line is, speaking nephrologist, that despite the best achievable care, patients are still progressing. I think that's the need. We hear that over and over again, that they just reach a certain point where, if you call it their optimized and standard of care, for lack of a better expression, if you will, these patients are still progressing, and nephrologists are kind of out of things to do at that point in time, other than just trying to do the absolute best. It becomes more of a when, not an if, they'll progress to dialysis. I think that gave us a lot of encouragement about the positioning, where we're studying the patients overall.
You've heard us say before, there's a very large TAM. There's over 1.1 million patients that fit that criteria of stage 3b/4 with type 2 diabetes. As we listen to nephrologists, I don't think patient identification is necessarily going to be a challenge for us overall. We'll get to manufacturing a little bit here, but in terms of our thought process at launch, we want to have a very kind of focused and purposeful launch. This is the first time this will be stood up within nephrology, and making sure that the patient, as they get diagnosed from a nephrologist and get ultimately referred to an interventional radiologist for treatment, we want to make sure that that kind of pathway is well-established and really goes well for the patient and the provider.
That is our biggest goal right now, is to, as we identify patients, ensure that the whole process is really smooth. We will start with a very focused and purposeful launch, probably eight to 10 centers located around the country, whereby we identify, you refer to as a center of excellence. We are going to refer to it as more of a renal partnership network, if you will, of facilities that have certified their trained IRs, and then we can canvas and call on the community nephrologists in that geography, help identify patients, and refer them into that appropriate treatment center. That will be our initial focus, and then as manufacturing continues to scale up, we can kind of validate that model and then replicate that model going forward as well.
Okay. Maybe you could talk a little more on the manufacturing side. We get that question a lot, sort of where you stand right now, kind of your plans on sort of doing this scale-up as you get closer to-
Yeah, I am happy to grab that. If you have not seen it in our updated corporate deck, we have a beautiful slide which actually depicts this kind of walkway, but I will try to visually walk you through it, if you will. Within the first three to four years, our goal is to build up our capacity where we will be able to have at least manufacturing capacity for approximately 3,000 patients, right? At launch, we will start with launching in our, as Bruce alluded to, we own our own manufacturing plant in Winston-Salem, North Carolina. At launch, we will have manufacturing capacity for about 350 patients. That is the same facility that is providing the clinical trial material for our phase III study. Within that facility, we also have the ability to do an expansion, and this will come in two different phases.
The first phase, which will take place in the second year through a tech transfer, will bring in additional capacity for 500 patients beyond that 350 in the first year, so an additional 500 in that second year. A lot of that work has already been done during 2026, so it is ready to go outside of a typical tech transfer. Phase II in that same facility replicates kind of phase I, right? That work will start in 2027. So by year three, we should be able to bring on capacity for an additional 500 patients. Then beyond that, at the facility, we have a couple different options. We could continue and do a further expansion of that facility. We could look at CDMOs. We could look at different geographical expansions as well, and that then gets us up into roughly about that 3,000 patients per year.
We have got a well-thought-through plan over the first, call it, three to four years of how to build up and scale our manufacturing capacity and provide ultimately the therapy for more patients.
Okay.
Vamil, obviously with really good data, then this becomes a money issue in how we scale. With really good data, I think with the right resources, we think we can also scale through the different options that Greg outlined.
Okay.
Even faster.
Maybe shifting gears a little bit. We saw you at ASN a couple weeks ago. You guys had a number of posters there. Common question we get is just sort of the understanding of how rilparencel is working. I am looking at Anthony. He is going to answer this question. Sort of kind of the work you have done there, your understanding at this point, kind of how the product works would be great to hear.
Yeah, absolutely. We had seven non-clinical presentations at ASN, including one oral presentation. Four of those were mechanism of action presentations and three drug product characterizations. High level, what we are seeing across all of our different CKD translational models is rilparencel is inducing a cytoprotective effect to diseased and injured kidney cells. We are seeing an improvement in oxidative damage, metabolic dysregulation, pro-inflammatory signaling to promote vascular integrity, and overall functional stabilization in both endothelial cells and epithelial cells in diseased and injured kidney cells. We are seeing rilparencel engrafts around kind of the subcapsular region of the injected kidney. We are also seeing new blood vessel formation in that region. We know rilparencel is secreting factors, and we are also seeing kind of a more systemic-wide improvement in kidney function.
All of that data taken together, were giving us relatively high confidence in explaining how rilparencel may be preserving kidney function in our clinical population.
Okay. This maybe builds on a couple of comments you made, but in this population, obviously, there is not a lot of other options, both from the clinical side and then maybe also commercially. How are you thinking about this being used on top of the current agents like the SGLT2s, the GLP-1s that have sort of emerged over the last several years, both so it does not sort of lead to any surprising results clinically, but also how you think about it from a patient population commercially?
I will speak to the RMAT first because we have an RMAT, and the way an RMAT works is that you need to demonstrate benefit above and beyond standard of care. The standard of care from the discussions with the FDA, which we would expect in our label too, to some degree, is that patients need to be on a RAS inhibitor, ACE or an ARB, need to be on an SGLT2 as well. We have taken all sort of operational means that we can, including putting that into our study protocol to ensure that patients are either on or have been on and failed RAS inhibition or SGLT2 inhibitor use. We also encourage a good standard of care in general, including GLP-1s. We expect, and we are seeing, a very high use of standard of care in patients within our trial.
We also expect that that's how it's going to be used in the real world, is that it's easier to put patients on small molecules, if you like, or weekly injections or biweekly injections at home. It's a lot easier to do that than to come into a clinic and get a biopsy and two injections. We expect standard of care is going to rule the day. We're going to be there for those patients who continue to progress and are still at high risk of kidney failure.
Is there anything in the trial, I guess, to just make sure it's balanced in terms of the use of the backup?
We expect randomization will do most of the balancing, but just to be careful on the SGLT2 inhibitor side, we stratify randomization based upon baseline SGLT2 use or not.
Okay. Okay. A couple other topics that come up frequently. I think we've seen cell therapies, a lot of promise scientifically and kind of getting in the market, but then struggle commercially, maybe for various reasons, whether manufacturing or finding the right patients. How are you sort of thinking about what have you learned maybe from some of these prior approaches other companies have taken? How are you addressing those to kind of have hopefully a more positive outcome here?
Maybe, Greg, I will hand it over to you first.
Yeah, I am happy to grab that. Ironically, I think I would start with manufacturing since we are on that topic. One of the nice things that we have in our manufacturing process is there is no viral vectors needed, there is no genetic modification required. What that translates to and why that is important is more from the patient perspective, right? The patient is not required. There is no immunosuppression, there is no special preconditioning, which importantly allows us to do this in an outpatient procedure, right? That is very different than a lot of other cell therapies.
From a patient journey, the overall complexity, even the manufacturing cost, if you will, it is a simpler, quote unquote, "process" despite the fact that we still need to do a biopsy and two injections. I would start there, just very different than a lot of our cell therapies, just be able to go directly to outpatient.
The other piece I would point to is, unlike a lot of other cell therapies, our population is just really, really large, right? This 1.1 million patients. Obviously, if you take that 1.1 million, you break that down, not everybody might be eligible, but you are talking hundreds of thousands of patients, which is really unique here from a TAM perspective. As I mentioned before, I think our ability to identify patients that are being treated but still progressing despite the best achievable care, we do not see that as a large issue right now. I think those two things speak to the fact that this could be very, very different than perhaps other cell therapies. A lot of other cell therapies that try to find that TAM and build that up, we have that existing.
We just need to figure out how to identify them and get them into treatment.
The other thing I'll add to that, if you don't mind, is we're on the right side of policy as well. There was an executive order in 2019, Advancing American Kidney Health. Last month, while we were at ASN, HHS built upon that executive order and rolled out their kidney care plan. Among three sort of pillars within that plan, one pillar was around addressing innovation to stabilize kidney function and prevent kidney failure. It didn't call us out, but that's exactly what we're doing. Kidney disease has bipartisan support, so I think at the policy level, we're also in a very good position to have a successful business.
I don't know how much you can share or how much you've shared before in terms of just how you're thinking about pricing for something like this, which obviously for a late stage, where there's not a lot of options for these patients, but also a pretty big population of patients potentially. I don't know, Greg, if you want to maybe share what you can around the-
Yeah. I mean, obviously, it's a little early to share really specifics on pricing as well, but as we've done, I will say one thing I'm really encouraged on, just to build off the last question as well, is the response from nephrologists so far, with just even an idea of what rilparencel could look like with a target product profile. They clearly see the need for their patients overall, and it's in the area that we're talking about. They're very intrigued by this novel cell therapy, right? There's nothing else like this within nephrology, so there are lots of questions on MOA and things like that, which Anthony thankfully is providing a lot of details for. But there's a lot of interest there as well. I think as we step back and look at it, a lot of this will be driven by the data, right?
Assuming the data is compelling as we expect it will be. You've got a couple different analogs that are out there. You've got cell therapy-like prices, right, which are pretty well established. You've had some recent advancements with other treatments in the kidney disease space as well, some of the rare disease products that are out there that are approaching cell therapy-like prices. As we start to step back and look at it, I think we're zeroing in on around that area. But again, we're early. Requires a little bit more research and thought process behind it as well.
Okay. And maybe last couple of topics I want to touch on. One is around IP or sort of protecting your innovation here. Maybe you can share both from a sort of true patent perspective, but also maybe just a know-how perspective, how you see yourselves defending your product.
Yes. There's a few things to address there. So one, in the corporate deck that we just released today, we actually have, I think for the first time, disclosed what our IP positioning is, and we're in a really, really strong position. There's also this sort of just know-how piece of making our product. So some of that's not captured in IP, but there is definitely a know-how that's protected in making our product, whether that's sort of the material that go into our product or actually how we make our product. So we think we're in a very, very strong position from an IP perspective.
Then put that aside, just to run a phase III trial like we have, get through a clinical development program to run a trial like we have, that creates even a little bit more of a moat, if you like, for other potential entrants coming in directly as a competitor.
Okay. Then just, I guess, looking forward now more from a big picture corporate level. So maybe you can talk about your cash position, and obviously the key event is the second quarter data readout next year. Aside from that, what are other events we should be looking forward to?
Yeah. We have an earnings release, I think, later this week, but in our corporate deck this morning, we released our position that we had $142 million in cash at the end of September. That's sufficient cash to take us out to mid-2027 after a readout. Again, that readout is clearly the big thing for us in 2027. We also, as you know, stopped recruitment. That doesn't mean we've stopped enrollment. Some of those patients who were screened and are eligible for the study, the last patients that we anticipate will get enrolled in Q1. So that's, I guess, a softer milestone along the way to actually the big readout in Q2.
Okay. One last question, a minute here. Just in terms of the commercial layout here again, it feels very U.S.-centric. Maybe can you talk at all about your thoughts or plans on kind of going broader than the U.S.? Also, I guess in the U.S., it feels like you could do something like this on your own with a targeted approach, but how are you thinking about the need for partners?
Yes. I will just say from a U.S. perspective, our sole focus since I have been CEO is U.S. Now, that can be criticized, because the population, the unmet need with the population here in the U.S. is so large, it is hard for us to distract our teams and start thinking about solutions outside the U.S. So that is why we are so focused on the U.S. Outside the U.S., we will be open clearly for more strategic partnerships. We really have not spent a lot of time on that just yet because our focus is getting to market in the U.S.
Okay. All right, great. I think with that, we will leave it there. Thanks so much for joining us again.